1.58
-0.09 (-5.39%)
| Previous Close | 1.67 |
| Open | 1.72 |
| Volume | 1,973,836 |
| Avg. Volume (3M) | 3,209,881 |
| Market Cap | 112,353,032 |
| Price / Sales | 17.52 |
| Price / Book | 2.09 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Operating Margin (TTM) | -9,653.85% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -12.20% |
| Total Debt/Equity (MRQ) | 24.34% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -49.55 M |
| Levered Free Cash Flow (TTM) | -27.61 M |
| Return on Assets (TTM) | -31.37% |
| Return on Equity (TTM) | -36.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ovid Therapeutics Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -1.33 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 55.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tls Advisors Llc | 30 Jun 2025 | 680,967 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Oct 2025 | Announcement | Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds |
| 03 Oct 2025 | Announcement | Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile |
| 13 Aug 2025 | Announcement | Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results |
| 23 Jul 2025 | Announcement | Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |